Axolabs is currently building a new site in Berlin for cGMP manufacturing of oligonucleotide therapeutics. The new state-of-the-art facility will operate as a Contract Development and Manufacturing Organization (CDMO) specializing in cGMP manufacturing of Active Pharmaceutical Ingredients (API). The facility will deliver oligonucleotide API from pre-clinical pilot scale to clinical and commercial process scale for our customers around the world.

The facility will initially be built on an area of 59,000 sqft and allows for an expansion of 16,000 sqft. The start of operations is planned for 2024.

Our team of experts has over 30 years of experience in the manufacture and analytical characterization of oligonucleotides and is well established in the oligonucleotide community.

This new facility allows the LGC Group expand its expertise in the field of nucleic acid-based therapeutics, which are already bundled in the companies Axolabs, Kulmbach, and Axolabs, Petaluma, USA.